« A successful biopharmaceutical company needs a pipeline of patented molecules that can become its next-generation therapeutic drugs. Patent protection is one of the most important aspects to protect the company`s assets and the investments of its shareholders, » commented Dr. Guy Chamberland, CEO and CRO of Tetra. Confluence Pharmaceuticals and AOP Orphan Pharmaceuticals AG recently announced that they have signed a final agreement for the joint development and commercialization of Confluence`s leading active ingredient, a product to treat Fragile X syndrome in Europe and the Middle East. Confluence is a biopharmaceutical company focused on developing therapeutic treatments for fragile X syndrome and autism spectrum disorders. AOP is an Austrian-based company specializing in the development and marketing of drugs for rare and complex diseases. About AOP Orphan Pharmaceuticals AG AOP is a pharmaceutical company specializing in the development and commercialization of drugs for rare and complex diseases in hematology/oncology, cardiovascular diseases, metabolic disorders and neurology. The company is present in all countries of Central Europe and the Middle East. AOP also markets its products in Southeast Asia, South Africa and South America with a number of distributors.

The company`s head office is located in Vienna, Austria. For more information, see www.aoporphan.at. MAKScientific is a recognized leader in endocannabinoid research and drug development. MAKScientific has developed a pipeline of low-molecule drugs that target cannabinoid receptors (CB1 and CB2) as well as other targets involved in the endocannabinoid system. As part of the agreement, MAKScientific will develop novel molecules that will be evaluated by Tetra to determine efficacy in different indications such as cancer, pain and inflammation, as well as other potential targets of interest to Tetra. Dublin, Feb. 03, 2020 (GLOBE NEWSWIRE) — The report « Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2019 » has been added to the ResearchAndMarkets.com. This report offers a comprehensive understanding and unprecedented access to co-development agreements and agreements reached by the world`s leaders in life science. This report provides details on the latest cooperation agreements announced in the pharmaceutical, biotechnology and diagnostic fields. The report, fully revised and updated, provides details on the development agreements co-financed from 2014 to 2019.Es, the parties are increasingly willing to conclude co-development agreements.

Such agreements allow both parties to enjoy the benefits of a large product gain, while traditional licensing agreements for advance payments, milestones and short-term licenses lose upward potential. Co-development partnerships allow parties to securitize value and reduce risk, but retain some of the potential upside potential if the product reaches the market. If the licensor does not market the project, it may sell these rights either to the licensee`s partner or to another partner for an amount greater than that which would have been obtained under a previous licence agreement.